Review



silver nanoparticles against e coli atcc  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    ATCC silver nanoparticles against e coli atcc
    Silver Nanoparticles Against E Coli Atcc, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 19 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/silver nanoparticles against e coli atcc/product/ATCC
    Average 95 stars, based on 19 article reviews
    silver nanoparticles against e coli atcc - by Bioz Stars, 2026-04
    95/100 stars

    Images



    Similar Products

    95
    ATCC silver nanoparticles against e coli atcc
    Silver Nanoparticles Against E Coli Atcc, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/silver nanoparticles against e coli atcc/product/ATCC
    Average 95 stars, based on 1 article reviews
    silver nanoparticles against e coli atcc - by Bioz Stars, 2026-04
    95/100 stars
      Buy from Supplier

    99
    ATCC apramycin silver nanoparticles against e coli atcc 25922 well
    Apramycin Silver Nanoparticles Against E Coli Atcc 25922 Well, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apramycin silver nanoparticles against e coli atcc 25922 well/product/ATCC
    Average 99 stars, based on 1 article reviews
    apramycin silver nanoparticles against e coli atcc 25922 well - by Bioz Stars, 2026-04
    99/100 stars
      Buy from Supplier

    99
    ATCC apramycin silver nanoparticles against e coli atcc 25922
    Apramycin Silver Nanoparticles Against E Coli Atcc 25922, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apramycin silver nanoparticles against e coli atcc 25922/product/ATCC
    Average 99 stars, based on 1 article reviews
    apramycin silver nanoparticles against e coli atcc 25922 - by Bioz Stars, 2026-04
    99/100 stars
      Buy from Supplier

    99
    ATCC silver nanoparticles against e coli atcc 25922
    Bacteriostatic effects of antimicrobial combinations against <t>E.</t> <t>coli</t> ATCC 25922: (a) apramycin–silver( i ) and (b) apramycin–silver nanoparticles. Absence of turbidity: grey. Presence of turbidity: white. Synergism: S. Indifference: I.
    Silver Nanoparticles Against E Coli Atcc 25922, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/silver nanoparticles against e coli atcc 25922/product/ATCC
    Average 99 stars, based on 1 article reviews
    silver nanoparticles against e coli atcc 25922 - by Bioz Stars, 2026-04
    99/100 stars
      Buy from Supplier

    Image Search Results


    Bacteriostatic effects of antimicrobial combinations against E. coli ATCC 25922: (a) apramycin–silver( i ) and (b) apramycin–silver nanoparticles. Absence of turbidity: grey. Presence of turbidity: white. Synergism: S. Indifference: I.

    Journal: Nanoscale Advances

    Article Title: Synergistic activity of silver nanoparticles and antibiotics: apramycin against Escherichia coli

    doi: 10.1039/d5na00404g

    Figure Lengend Snippet: Bacteriostatic effects of antimicrobial combinations against E. coli ATCC 25922: (a) apramycin–silver( i ) and (b) apramycin–silver nanoparticles. Absence of turbidity: grey. Presence of turbidity: white. Synergism: S. Indifference: I.

    Article Snippet: To the best of authors' knowledge, this is the first study to evaluate the combination of apramycin with silver( i ) and silver nanoparticles against E. coli ATCC 25922.

    Techniques:

    Bactericidal effects of antimicrobial combinations against E. coli ATCC 25922: (a) apramycin–silver( i ) and (b) apramycin–silver nanoparticles. Absence of turbidity: grey. Presence of turbidity: white. Synergism: S. Indifference: I. *: bacterial growth.

    Journal: Nanoscale Advances

    Article Title: Synergistic activity of silver nanoparticles and antibiotics: apramycin against Escherichia coli

    doi: 10.1039/d5na00404g

    Figure Lengend Snippet: Bactericidal effects of antimicrobial combinations against E. coli ATCC 25922: (a) apramycin–silver( i ) and (b) apramycin–silver nanoparticles. Absence of turbidity: grey. Presence of turbidity: white. Synergism: S. Indifference: I. *: bacterial growth.

    Article Snippet: To the best of authors' knowledge, this is the first study to evaluate the combination of apramycin with silver( i ) and silver nanoparticles against E. coli ATCC 25922.

    Techniques:

    Silver mass per bacteria distributions analysed by SC-ICP-MS for samples of E. coli ATCC 25922 bacteria exposed to: (a) 0.50 mg L −1 Ag( i ), (b) 0.50 mg L −1 Ag( i ) + 0.25 mg L −1 apramycin and (c) 0.50 mg L −1 Ag( i ) + 2 mg L −1 apramycin.

    Journal: Nanoscale Advances

    Article Title: Synergistic activity of silver nanoparticles and antibiotics: apramycin against Escherichia coli

    doi: 10.1039/d5na00404g

    Figure Lengend Snippet: Silver mass per bacteria distributions analysed by SC-ICP-MS for samples of E. coli ATCC 25922 bacteria exposed to: (a) 0.50 mg L −1 Ag( i ), (b) 0.50 mg L −1 Ag( i ) + 0.25 mg L −1 apramycin and (c) 0.50 mg L −1 Ag( i ) + 2 mg L −1 apramycin.

    Article Snippet: To the best of authors' knowledge, this is the first study to evaluate the combination of apramycin with silver( i ) and silver nanoparticles against E. coli ATCC 25922.

    Techniques: Bacteria

    Silver mass per bacteria distributions analysed by SC-ICP-MS for samples of E. coli ATCC 25922 bacteria exposed to: (a) 2 mg L −1 AgNPs, (b) 2 mg L −1 AgNPs + 0.25 mg L −1 apramycin and (c) 2 mg L −1 AgNPs + 2 mg L −1 apramycin.

    Journal: Nanoscale Advances

    Article Title: Synergistic activity of silver nanoparticles and antibiotics: apramycin against Escherichia coli

    doi: 10.1039/d5na00404g

    Figure Lengend Snippet: Silver mass per bacteria distributions analysed by SC-ICP-MS for samples of E. coli ATCC 25922 bacteria exposed to: (a) 2 mg L −1 AgNPs, (b) 2 mg L −1 AgNPs + 0.25 mg L −1 apramycin and (c) 2 mg L −1 AgNPs + 2 mg L −1 apramycin.

    Article Snippet: To the best of authors' knowledge, this is the first study to evaluate the combination of apramycin with silver( i ) and silver nanoparticles against E. coli ATCC 25922.

    Techniques: Bacteria

    Percentage of silver-containing bacteria E. coli ATCC 25922 in relation to total bacteria. Exposed silver concentration: 0.50 mg L −1 Ag( i ) and 2 mg L −1 10 nm AgNPs.

    Journal: Nanoscale Advances

    Article Title: Synergistic activity of silver nanoparticles and antibiotics: apramycin against Escherichia coli

    doi: 10.1039/d5na00404g

    Figure Lengend Snippet: Percentage of silver-containing bacteria E. coli ATCC 25922 in relation to total bacteria. Exposed silver concentration: 0.50 mg L −1 Ag( i ) and 2 mg L −1 10 nm AgNPs.

    Article Snippet: To the best of authors' knowledge, this is the first study to evaluate the combination of apramycin with silver( i ) and silver nanoparticles against E. coli ATCC 25922.

    Techniques: Bacteria, Concentration Assay

    SEM images (10000×) of E. coli ATCC 25922: (a) control and exposed to (b) 2 mg L −1 apramycin, (c) 2 mgL −1 10 nm AgNPs and (d) 2 mg L −1 apramycin + 2 mg L −1 10 nm AgNPs.

    Journal: Nanoscale Advances

    Article Title: Synergistic activity of silver nanoparticles and antibiotics: apramycin against Escherichia coli

    doi: 10.1039/d5na00404g

    Figure Lengend Snippet: SEM images (10000×) of E. coli ATCC 25922: (a) control and exposed to (b) 2 mg L −1 apramycin, (c) 2 mgL −1 10 nm AgNPs and (d) 2 mg L −1 apramycin + 2 mg L −1 10 nm AgNPs.

    Article Snippet: To the best of authors' knowledge, this is the first study to evaluate the combination of apramycin with silver( i ) and silver nanoparticles against E. coli ATCC 25922.

    Techniques: Control

    TEM images (250 00×–100 000×) of bacteria E. coli ATCC 25922: (a) control and exposed to (b) 2 mg L −1 apramycin, (c and d) 2 mg L −1 10 nm AgNPs, and (e and f) 2 mg L −1 10 nm AgNPs + 2 mg L -1 apramycin. Red arrows: shrinkage and heterogeneity of the cytoplasm. Red circles: membrane rupture and cytoplasm leakage.

    Journal: Nanoscale Advances

    Article Title: Synergistic activity of silver nanoparticles and antibiotics: apramycin against Escherichia coli

    doi: 10.1039/d5na00404g

    Figure Lengend Snippet: TEM images (250 00×–100 000×) of bacteria E. coli ATCC 25922: (a) control and exposed to (b) 2 mg L −1 apramycin, (c and d) 2 mg L −1 10 nm AgNPs, and (e and f) 2 mg L −1 10 nm AgNPs + 2 mg L -1 apramycin. Red arrows: shrinkage and heterogeneity of the cytoplasm. Red circles: membrane rupture and cytoplasm leakage.

    Article Snippet: To the best of authors' knowledge, this is the first study to evaluate the combination of apramycin with silver( i ) and silver nanoparticles against E. coli ATCC 25922.

    Techniques: Bacteria, Control, Membrane